RNAZ (TransCode Therapeutics) NonCurrent Deferred Liabilities: $0.46 Mil (As of Mar. 2026)


RNAZ TransCode Therapeutics Inc RNAZ
32 GF Score
Price $7.77
! 1 Warning Sign
View Full Analysis

What is TransCode Therapeutics NonCurrent Deferred Liabilities?

TransCode Therapeutics RNAZ -9.76% 32 NonCurrent Deferred Liabilities is $0.46 Mil as of Mar. 2026. GuruFocus rates RNAZ with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

Non-Current Deferred Liabilities represents the non-current portion of obligations, which is a liability that usually would have been paid but is now pas due.

TransCode Therapeutics's non-current deferred liabilities for the quarter that ended in Mar. 2026 was $0.46 Mil.

TransCode Therapeutics NonCurrent Deferred Liabilities Related Terms

TransCode Therapeutics NonCurrent Deferred Liabilities Historical Data

* Premium members only.

The historical data trend for TransCode Therapeutics's NonCurrent Deferred Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TransCode Therapeutics NonCurrent Deferred Liabilities Chart

TransCode Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
NonCurrent Deferred Liabilities
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.23

TransCode Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
NonCurrent Deferred Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.23 0.46
RNAZ
32GF Score
TransCode Therapeutics Inc RNAZ
NonCurrent Deferred Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a NonCurrent Deferred Liabilities of $0.46 Mil mean?
TransCode Therapeutics (RNAZ) has a NonCurrent Deferred Liabilities of $0.46 Mil as of Mar. 2026. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on TransCode Therapeutics and its competitors.
Is TransCode Therapeutics' NonCurrent Deferred Liabilities too high?
TransCode Therapeutics' current NonCurrent Deferred Liabilities is $0.46 Mil. Overall, TransCode Therapeutics has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TransCode Therapeutics' NonCurrent Deferred Liabilities compare to ENSC and ALZN?
TransCode Therapeutics' NonCurrent Deferred Liabilities of $0.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good NonCurrent Deferred Liabilities for a Biotechnology company?
A good NonCurrent Deferred Liabilities depends on the Biotechnology industry context. However, NonCurrent Deferred Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high NonCurrent Deferred Liabilities mean?
A high NonCurrent Deferred Liabilities can signal that a stock is expensive relative to its fundamentals. Non-current deferred liabilities represent the company obligations not paid yet not due within the current period. View historical data on TransCode Therapeutics and its competitors. TransCode Therapeutics's current NonCurrent Deferred Liabilities is $0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransCode Therapeutics stock overvalued right now?
TransCode Therapeutics (RNAZ) has a current NonCurrent Deferred Liabilities of $0.46 Mil. The current NonCurrent Deferred Liabilities is $0.46 Mil. TransCode Therapeutics' overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is NonCurrent Deferred Liabilities calculated?
NonCurrent Deferred Liabilities is calculated from a company's financial statements. For TransCode Therapeutics (RNAZ), the current NonCurrent Deferred Liabilities is $0.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TransCode Therapeutics Business Description

Address 6 Liberty Square, No. 2382, Boston, MA, USA, 02109
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
32GF Score

Get the complete analysis for RNAZ

NonCurrent Deferred Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.77
Price